The importance of elevated CDC37 and Aha1 and decreased levels of PP5 in AD tissue and their interplay with FKBP51 remains to be seen, but encouraged by our initial findings, we are now actively developing LA1011 and evaluating derivatives toward developing a clinical trial candidate against AD. This evidence concerns the gene FKBP4 and Alzheimer disease.